cancer-therapy

Documents about cancer-therapy

• Figure 6 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246358Figshare
• Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)#390927ClinicalTrials.gov
• Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer#4488Europe PMC
• Long-Term Outcomes, Moderators, and Predictors in Online Mindfulness-Based Cognitive Therapy for People With Cancer: Secondary Analysis of a Randomized Controlled Trial.#30851NCBI PubMed Central
• Identifying the Initiation of a New Line of Therapy for Metastatic Lung, Breast, and Colorectal Cancer in Real-World Data: A Scoping Review.#143156NCBI PubMed Central
• Prediction Model for Overall Survival in Patients with Epithelial Ovarian Cancer Undergoing Surgery and Systemic Therapy Based on the 2010–2021 SEER Database.#151447NCBI PubMed Central
• Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers#179020Lund University Publications
• Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study#181777ClinicalTrials.gov
• FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma#226259ClinicalTrials.gov
• Effectiveness of RMSSD-Based Adaptive Music Therapy (Skitii) in Reducing Treatment-Related Anxiety in Head and Neck Cancer Patients: Protocol for a Randomized Controlled Trial#271996bioRxiv / medRxiv
• The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction#272356ClinicalTrials.gov
• Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma#314351ClinicalTrials.gov
• Patient-reported distress and correlates while on adjuvant endocrine therapy following breast cancer treatment among post-menopausal women: a group-based trajectory model analysis.#317626NCBI PubMed Central
• Multimodal profiling for prediction of primary resistance to anti-PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers study#429584bioRxiv / medRxiv
• Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors#460088ClinicalTrials.gov
• Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance#464245HAL (France)
• Calcium overload-induced apoptosis in cancer cells: ER-mitochondria crosstalk and therapeutic implications#478481Europe PMC
• Baseline and early 18F-FDG PET/CT evaluations as predictors of progression-free survival in metastatic breast cancer patients treated with targeted anti-CDK therapy#676820HAL (France)
• Cardiologist-Performed Baseline Evaluation with an Assessment of Coronary Status for Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Impact on Newly Diagnosed Coronary Artery Disease#677098HAL (France)
• Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization’s database#677105HAL (France)
• Left bundle branch pacing vs biventricular pacing in heart failure patients undergoing cardiac resynchronization therapy: an updated systematic review and meta-analysis#424553Figshare
• Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial#231578HAL (France)
• Supplementary Figure S1 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246359Figshare
• Supplementary Figure S2 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246360Figshare
• Supplementary Figure S3 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246361Figshare
• Supplementary Figure S4 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246362Figshare
• Supplementary Figure S5 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246363Figshare
• Supplementary Figure S6 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246364Figshare
• Supplementary Figure S7 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246365Figshare
• Supplementary Figure S8 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246366Figshare
• Supplementary Table 1 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246367Figshare
• Supplementary Table 2 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246368Figshare
• Development and Validation of an E-learning Module on Systemic Anticancer Therapy and Its Effectiveness on the Knowledge Attitude and Practice of Nurses in Administering Systemic Anticancer Agents at a Specialized Cancer Centres in Oman.#369843ClinicalTrials.gov
• Separable Microneedles Composed of Hyaluronic Acid Derivatives and Acid-Labile Linkages for Transdermal Delivery of Biomimetic Nanoparticles and Synergistic Breast Cancer Therapy#382014Figshare
• Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer#238105ClinicalTrials.gov
• Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy#614719eScholarship
• Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)#314328ClinicalTrials.gov
• HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions#146249ClinicalTrials.gov
• Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease#172327ClinicalTrials.gov
• Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA#180383ClinicalTrials.gov
• Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer#222651IRIS
• Standardized Program of Resistance Training for Prostate Cancer Patients Receiving Androgen Deprivation Therapy (SPoRT-PCa-ADT): study protocol for a randomized controlled trial.#265609NCBI PubMed Central
• Construction and validation of a pretreatment DCE-MRI-based radiomics prediction model for axillary pathologic response after neoadjuvant therapy in node-positive breast cancer.#280912NCBI PubMed Central
• Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma#356540ClinicalTrials.gov
• Socioeconomic Determinants of Guideline-Concordant Therapy for Early-Stage Non-Small Cell Lung Cancer: A Population-Based Analysis from Appalachian and Non-Appalachian Ohio, 2004-2015#390893bioRxiv / medRxiv
• [(18)F]FDG PET/MRI for axillary staging in node positive breast cancer patients receiving primary systemic therapy. A prospective single arm trial.#422950NCBI PubMed Central
• Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever#429771ClinicalTrials.gov
• Discovery of Novel AURKA Inhibitors for Triple-Negative Breast Cancer (TNBC) Therapy via a Hybrid Virtual Screening Pipeline, Biological Evaluation and Molecular Dynamics Simulation.#438966NCBI PubMed Central
• Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma#444807ClinicalTrials.gov
• How to optimise prostate SBRT: ESTRO clinical practice consensus recommendations#468402HAL (France)